 - TRC105 is a genetically engineered humanmurine chimeric monoclonal antibody that inhibits angiogenesis and tumor growth via endothelial cell growth inhibition and apoptosis. TRC105 is directed against human CD105 endoglin, an angiogenic membrane protein that is highly expressed on proliferating vasculature in solid tumors and up-regulated following anti-VEGF vascular endothelial growth factor therapy. Clinical studies in bladder cancer with anti-angiogenic agents have shown anti-tumor activity. 